Plain English Summary
Background and study aims
Osteoarthritis, a common joint disorder, is the most common form of arthritis in the world. The knee joint is the most common site affected by osteoarthritis. Joint pain caused by knee osteoarthritis can severely reduce the patient’s quality of life. The aim of this study is to compare the effects of jade moxibustion and traditional moxibustion on knee pain in osteoarthritis.
Who can participate?
Patients aged 50 to 75 undergoing conventional knee osteoarthritis treatment
What does the study involve?
Participants are randomly allocated to be treated with either jade moxibustion or traditional moxibustion at the acupoints on the affected knee(s). Patients in both groups receive 20 minutes of treatment, three times per week for 4 weeks. The effects of treatment are assessed through questionnaires at the start of the study and at 2, 4, 8, 12 and 24 weeks after they join the study. The assessments will take place at either Tongren Hospital or Shanghai Pudong Hospital except for the assessment at 24 weeks, where the questionnaire will be mailed to participants.
What are the possible benefits and risks of participating?
Jade moxibustion and traditional moxibustion can reduce pain and improve knee joint stiffness and function in patients with knee osteoarthritis. Some patients might have local skin flushing or blistering (not instantly, but usually one day after treatment) at the site of treatment. Usually, the blister is naturally absorbed within a day or two without obvious scarring of the skin.
Where is the study run from?
1. Tongren Hospital Affiliated to Shanghai Jiaotong University (China)
2. Shanghai Pudong Hospital of Traditional Chinese Medicine (China)
When is the study starting and how long is it expected to run for?
May 2019 to June 2021
Who is funding the study?
Shanghai Key Laboratory of acupuncture mechanism and acupoint function (China)
Who is the main contact?
Prof. Xueyong Shen
sxy1@shutcm.edu.cn
Trial website
Contact information
Type
Scientific
Primary contact
Mr Xueyong Shen
ORCID ID
Contact details
Shanghai University of Traditional Chinese Medicine
1200 Cailun Road
Pudong New District
Shanghai
201203
China
+86 2151322175
sxy1@shutcm.edu.cn
Type
Public
Additional contact
Mr Lusheng Chen
ORCID ID
http://orcid.org/0000-0001-9618-3080
Contact details
Shanghai University of Traditional Chinese Medicine
1200 Cailun Road
Pudong District
Shanghai
201203
China
+86 13681913509
13681913509@163.com
Additional identifiers
EudraCT number
Nil known
ClinicalTrials.gov number
Nil known
Protocol/serial number
Nil known
Study information
Scientific title
Comparison of the efficacy of jade moxibustion and traditional moxibustion in knee osteoarthritis: a pilot randomized clinical trial
Acronym
Study hypothesis
A 4-week jade moxibustion treatment regimen will reduce pain among patients with knee osteoarthritis as compared with traditional moxibustion treatment, and the therapeutic effect might be related to the cytokines such as Interleukin in serum.
Ethics approval
Approved 10/07/2019, Institutional Review Board (IRB) of Tongren Hospital Affiliated to Shanghai Jiaotong University (Room 309, Building 6-3, 1111 Xianxia Road, Changning District, Shanghai, China, 201103; +86 (021) 52039999-96341), ref: 2019-022-02
Study design
Randomized controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details to request a participant information sheet
Condition
Knee osteoarthritis
Intervention
Patients with knee osteoarthritis are randomly allocated into either jade moxibustion or traditional moxibustion groups.
Patients will receive jade moxibustion or traditional moxibustion treatment on ST35, ST34, EX-LE4, SP10 and Ashi points in the area of the affected knee(s). Patients in both groups receive 20 minutes of treatment, 3 times per week for 4 weeks.
The effects of treatment on the most painful joint (which is identified through participant report at baseline and is the joint assessed throughout the study) are assessed at the hospital at baseline, 2 (mid-term), 4 (the end of treatment), 8, and 12 weeks after baseline. During the follow-up period (5 to 24 weeks), the subject report on adverse events and side effects will be sought via telephone call weekly. At 24 weeks, the questionnaire will be mailed to the subjects and they will be asked to post them back after filling them out.
Participants will be allowed to take any analgesic or non-steroidal anti-inflammatory drugs that they used before the study. They will be asked to record the daily dose during the entire clinical trial, and then the investigators will analyze the changes in the dose.
Intervention type
Other
Phase
Drug names
Primary outcome measure
Knee pain, measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at baseline and 2, 4, 8, 12, and 24 weeks
Secondary outcome measures
1. Knee function measured using the WOMAC function score at baseline, weeks 2, 4, 8, 12, and 24 weeks
2. Knee stiffness measured using the WOMAC stiffness score at baseline, weeks 2, 4, 8, 12, and 24 weeks
3. Knee osteoarthritis symptoms measured using the WOMAC total score at baseline, weeks 2, 4, 8, 12, and 24 weeks
4. Knee pain measured using the Visual Analogue Scale (VAS) pain score at baseline, weeks 2,4, 8, 12, and 24 weeks
5. Sensation measured by investigator question "What do you feel during the treatment?" (with possible answers of: heat, cold, pain, no feeling, or other which will be described)
6. Quality of life measured using the 36-Item Short Form Health Survey (SF-36) at 4, 12 and 24 weeks and the Quality of Life Scale (QOLS) at 4 weeks
7. Participant perception of the safety of the treatment measured by investigator question (with possible answers of: safe, less safe, safety problem, or serious safety problem) at 4 weeks
8. Dose of analgesic or non-steroidal anti-inflammatory drugs consumed, determined through daily participant reports from baseline to 24 weeks
9. Any adverse events or side effects during the study are determined from the subject and investigator reports collected weekly from baseline to 24 weeks. Common side effects include redness and blisters by jade moxibustion and traditional moxibustion. Serious adverse events will also be reported to the Ethics Committee
Overall trial start date
01/05/2019
Overall trial end date
30/06/2021
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Aged 50 to 75 years
2. Knee osteoarthritis according to the American College of Rheumatology Diagnostic Criteria
3. Radiologic confirmation of knee osteoarthritis (Kallgren-Lawrence level ≥1)
4. Moderate to severe knee pain on most days of the past month (VAS score for arthritic pain ≥40)
5. Has a full understanding and gives informed consent to participate in the study
Participant type
Patient
Age group
Senior
Gender
Both
Target number of participants
148
Participant exclusion criteria
1. Knee pain caused by other diseases (such as rheumatoid arthritis, fibromyalgia syndrome, chronic fatigue syndrome, and ankylosing spondylitis)
2. Treatment with steroid drugs in the past 3 months
3. Received acupuncture or moxibustion treatment in the past 3 months
4. Intra-articular injection of hyaluronate in the past 6 months
5. Joint puncture or arthroscopy in the past year
6. Previous (or planned for during the trial) knee or hip replacement surgery
7. Use of other topical treatments for osteoarthritis of the knee
8. Diagnosis of any serious diseases including, but not limited to, heart disease, lung disease, kidney disease, liver disease, malignant tumor, systemic infection, infectious disease, and/or mental illness
9. Participation in another clinical study in the past month
Recruitment start date
10/07/2019
Recruitment end date
31/12/2020
Locations
Countries of recruitment
China
Trial participating centre
Tongren Hospital Affiliated to Shanghai Jiaotong University
No.1111
Xianxia Road
Changning District
Shanghai
200336
China
Trial participating centre
Shanghai Pudong Hospital of Traditional Chinese Medicine
No. 399
Pingchuan Road
Pudong New District
Shanghai
201200
China
Sponsor information
Organisation
Shanghai University of Traditional Chinese Medicine
Sponsor details
1200 Cailun Road
Pudong new district
Shanghai
201203
China
+86 (0)21 51322042
kyctcm@vip.sina.com
Sponsor type
University/education
Website
Funders
Funder type
Industry
Funder name
Shanghai Key Laboratory of Acupuncture Mechanism and Acupoint Function
Alternative name(s)
SKLAA
Funding Body Type
private sector organisation
Funding Body Subtype
Research institutes and centers
Location
China
Results and Publications
Publication and dissemination plan
Planned publication in a peer reviewed medical journal and planned presentations at local and international conferences.
IPD sharing statement:
The datasets generated during and/or analysed during the current study are/will be available upon request from Prof. Xueyong Shen (sxy1@shutcm.edu.cn) or Dr Lusheng Chen (13681913509@163.com).
Intention to publish date
30/04/2021
Participant level data
Available on request
Basic results (scientific)
Publication list